Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I would not be surprised to hear that Dr Patterson greatly regrets her decision to give her invention in the hands of crooks and inept bipedals who have been running Advaxis for years. These a$$holes did everything possible and impossible to literally bury the LM platform -- an invention that had a potential if not to cure cancer but at least to get her a Nobel prize in medicine.
What a shame!
Don't worry, we have an AXALlent Science here.
Can we all find a consensus here, and say, it's medium cell.
But, the trophy goes to those who say it's non-small cell lung cancer (NSCLC).
I can count what's delivered. There is no way for us to know what's been done behind the curtains. Once I see something tangible, the list would be no longer empty. His tenure has been long enough to deliver something, besides that ill conceived warrants-laden secondary.
One way or another, he gets paid regardless what he gets done. Although some other companies are also infected with same get-paid-for-doing-nothing virus, they are in minority, where Advaxis stands. Remember, Lombardo got paid handsomely for warming the chair for a long time.
750k in stock options, which have not vested.
Correct. However, this is from Form 4:
2. Awarded as an inducement grant of stock options pursuant to the reporting person's employment agreement dated April 23, 2018. One-third of the award will vest on December 31, 2018, one-third will vest on April 23, 2020, and the award will be fully vested on April 23, 2021.
As the exercise price is $1.62, he might be tempted to do a reverse split and, thus, he would make out like a bandit.
Fear is the reason so many stay poor and the ratio at these prices for this company a compelling buy
Really? Fear and greed are two powerful forces that govern this stock market. If you lack either, you most likely end up poor. Not because you fear.
I don't see it that way, and the markets seem to agree with me here. The ratio will be even better if this stalemate continues.
Averaging down would work if and only if you know the company will deliver at some point. Otherwise, it's throwing good money after the bad.
Monday morning tidbits:
1) KB has been with Advaxis 7 months, and made $453,000 from his base salary and a one time bonus; plus, he got 1,000,000 shares of Advaxis as stock options and RSUs now worth about $470,000. Not a bad payday for a 7-months long effort!
2) He also accomplished the following:
<empty list>
I'm happy to have him on board! He's doing all righ!
@wmtgreeter
At this rate of destruction, it wouldn’t take more than two months. Patience...
However, the ADRO's and ADXS's market cap ratios still hover around 6:1 to 7:1 regardless how low we go. Things are going to be different when we approach the singularity at 0.
PPS is up
Yes, it's up by a whole penny. To da moon, Zoltie! Try not to clutter when the share price is down -- you would not be posting most of the trading days.
Another brand new multi-year low printed at 0.4200. Nothing to worry about, it's just a plain HeFTy, ALGOholic manipulation.
Congratulations on retaining your crystal clear vision during these turbulent times!
Wednesday morning tidbits:
1) Advaxis has not updated the corporate presentation file for November;
2) Ken Berlin is NOT presenting at Piper Jaffray 30th Annual Healthcare Conference;
3) Turkey "Advaxis" was pardoned @ WH yesterday (recall DOC had connections there!).
All the above points towards an imminent buyout by February 11.
You repeating about HFT/manipulation ad nauseam does not make it true either.
They will likely release clinical data for NEO late May/early June during ASCO-19. By that time, they'll be running extremely low on cash, and would be reckless to go below $20M of cash (just over a quarter of cash runway). How exactly they will replenish their cash needs? Or, are they going to take chances and ride it out till the end?
Of course, there is always a chance that a great positive results from PSA trial would force MRK to cough up some cash via an expansion of their current "partnership". But the data must be really good, or great. Will it happen? Nobody can tell that now.
Advaxis management has cornered themselves into the corner, and they do not have too many options now. Look at the last raise. When you see warrants, it's already a red flag.
A conventional equity market is now pretty much closed for Advaxis. The burning question is how they are going to finance their operations in the future if they are not able to get cash deals or release clinical data that should drive the market cap beyond $100M.
As our market cap is almost at $30M now, I have to say we are in an extremely dangerous territory. I have always said that a $30M MC is a threshold for a collapse. It's going to be extremely difficult now to escape from these gravitational forces once you cross the line of no return.
[color=red] Considering the carnage in the market, our puppy is holding up pretty well.
Bios turned to green or neutral, and our sick puppy just printed brand new multi-year low. Down almost 9%. This is how much confidence this market has in Advaxis.
#marriedtothestock
You might have said your vows.
Till death do us part.
#ADXS4ever
Now that we see that we have been trading around a cash value, or may even dip below it, this article is a good read why this happens:
https://www.investopedia.com/articles/stocks/09/companies-trade-for-less-than-cash.asp
Cheap Stocks or Value Traps? By Investopedia Staff | Updated January 17, 2018 — 4:22 PM EST
Under certain infrequent circumstances, a stock will trade for less than the amount of net cash per share on the company's balance sheet. Net cash per share is defined as cash and equivalents minus total debt, divided by the total number of shares outstanding of the company.
While such a stock may appear to be an irresistible bargain, a considerable amount of analysis is needed to determine whether it is a good deal or too good to be true.
Net Cash Per Share
As an example, consider a hypothetical company called Bargain Basement Co.—BBC, for short—with stock that is trading at $10, with 10 million shares outstanding. Assume that this company's latest balance sheet shows a cash holding of $150 million, with total debt of $25 million. Therefore, the net cash balance (cash minus debt) amounts to $125 million, and net cash per share is $12.50.
Why is the net cash figure used, rather than just the cash amount on the balance sheet?
Because the object of the exercise is to evaluate the net cash amount that would theoretically be received by equity shareholders in the event of the company's liquidation. Therefore, any debt outstanding has to be subtracted to arrive at the net cash figure.
Note that the net cash per share metric does not consider the value of other assets, such as inventories. It only provides part of the picture as far as a company's value is concerned, whereas a measure, such as tangible book value (book value minus intangible assets, like goodwill) may provide a more complete picture.
Enterprise Value
Here's another way of looking at this metric. A company with stock that is trading below its per-share cash value will have a market capitalization that is less than the net cash amount on its balance sheet. In the previous example, BBC has a market capitalization of $100 million, as compared with its net cash balance of $125 million.
In other words, the enterprise value of BBC is -$25 million. Enterprise value is the value of the whole business; in its simplest form, it is defined as market value of equity plus debt minus cash and equivalents. In BBC's case, this works out to $100 million (equity) plus $25 million (debt) minus $150 million (cash).
The value of a company lies in its ability to generate positive cash flows for years or decades into the future. But how can a company have a negative enterprise value, or be valued at less than its cash holding?
When Does a Stock Trade Below Cash Value?
As is to be expected, stocks rarely trade below cash value. However, under certain circumstances, such as those listed below, they may do so:
In bullish markets, since investors are willing to pay higher valuations for stocks, they seldom trade below cash value. However, during a protracted bear market—when uncertainty reigns and valuations collapse—it is not unusual to find a significant number of stocks trading below cash value. For example, in October 2008, as global financial markets were caught up in an unprecedented sell-off, more than 875 stocks were reportedly trading below the value of their per-share cash holdings.
Stocks trading below net cash may be clustered in a specific industry or sector if investors are extremely bearish regarding the prospects of that sector. For example, following the "tech wreck" of 2000 to 2002, a number of technology stocks were trading below the value of their net cash holdings.
A stock may also trade below cash value if the company operates in a sector such as biotechnology, where a high "burn rate" (the rate at which cash gets used up for operations) is the norm and the payoff is uncertain. In such cases, this may signal that the market views the company's cash balance as only being sufficient for a few more quarters of operations.
Stocks may also trade below cash value when there is a great deal of uncertainty about the valuation of assets and liabilities on the balance sheet. During the ferocious bear market of 2008, a number of banks and financial institutions traded below cash value for this reason.
Sign of Value or Impending Failure?
??The fact that a stock is trading below its cash value may be an indication that investors think the company is worth less as a going concern than it would be if it were wound up or liquidated (and the proceeds distributed to investors). This generally indicates an extremely pessimistic view of a company's prospects that eventually may or may not prove to be justified.
A stock trading below cash value may be a true value stock in situations where the pessimism surrounding its prospects is not justified. This could occur when a company is in the early stages of a turnaround and its business outlook is improving, or when a company is developing a drug or technology in which the chances of success are viewed with undue skepticism by investors.
A stock trading below cash value may signal impending failure in cases where the company may be unable to raise additional capital before its cash runs out or there are significant liabilities that may not be apparent on the balance sheet (e.g. a pending lawsuit or environmental issues).
In most cases, as noted earlier, a stock that is trading below net cash per share is not necessarily a bargain and it is necessary to look behind the numbers to identify the reason for the anomaly.
When to Invest
Broadly speaking, it may be best to invest in stocks trading below net cash value when market sentiment is positive and equities are in a firm uptrend. As such, the best time to do so is at the start of a new, sustainable bull leg before such stocks attract broad market attention. In 2003, for example, investors were able to reap substantial gains on select technology stocks that had traded below cash value for months beforehand.
Note that the majority of stocks trading below cash value are likely to be small-capitalization stocks that have been ignored by investors and the media. There is generally too much investor and media interest in larger stocks for them to trade below cash value for long. Small-cap stocks have their own unique risks, and investors looking to invest in them must ensure that they are familiar with these risks and can tolerate them.
A stock with sound fundamentals will seldom trade below cash value for long. Once market sentiment improves, investors usually catch on and stampede into it, thereby driving up the stock price. Otherwise, it is likely to be acquired by a rival company.
The Bottom Line
The initial impression of a stock that is trading at less than net cash per share may be that it is a bargain. However, it is recommended that an investor contemplating an investment in such a stock do a significant amount of analysis and look behind the numbers to ascertain whether it is a genuine bargain or a "value trap."
What kind of bird is Advaxis? Cold turkey or hot Phoenix? Are we going to rise from the ashes?
The answer will be delivered in few months from now.
So then we should just sit idly
Another buyout hysteria. Re-ignites every two months now. How many conspiracy theories have we heard, and likely many more to come.
#pathetic
“stock is IBM”
——————————-
I Bought More?
Sounds like it’s time to cover my short and switch the direction of my HeFTy algos. I am scared for the 567th times today regarding my Advaxis position.
What did I miss?
An AI generated single sentence mentioning dozens of stocks is now considered a pumping
Wrong. Deals could be signed before clinical data is made public. You never know.
if only one could go back in time!
I need to pinch myself...
Are we really close to capitulation now?
We? Us as shareholders or "us" as in the management? I'm sure the top management will not hesitate to issue year end bonuses and options to themselves. It's what they do, and it's the reason they ruin this company. To the ground.
I posted this 5 weeks ago. Out of $15M, they already received $12.5M leaving us with $2.5M max likely split between 2018 and 2019.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144138612
Maybe. The could get as much as $2.5M max as they have already received $12.5M of those tax credits over the years. Note the maximum lifetime "benefit" is $15M. Here is the timeline of those credits received:
Year Tax credit, $M
2012 0.725
2013 1.1
2014 1.7
2015 1.6
2016 2.5
2017 4.8
2018 (max 2.5)
If your ID is correct, your gold bullion is just 0.7% pure. Far away from 99.9% purity that you tend to compare ADXS to.
It's not about shorts/shorting anymore. Short numbers are down, so is the share price. The latter keeps going down as the funds/retail continue unloading their positions. There is not support, not much buying anymore for a long period of time. Thus, we continue a downdrift. Plain and simple.
PS. This is now really scary. Anyone besides Mr Salmon is buying? Is Mr Trout buying?
A brand new low...
Pathetic.
Time for the management to issue new RSUs.
Dafna Capital Mngmt: increased their position by 970K shares, now hold 1.667M shares (likely participated in the recent 2ndary)
DE Shaw & Company: increased by 156K shares, hold 793K shares
DAFNA CAPITAL MANAGEMENT LLC 1,666,666 0.47 42 969,666 3.1673% 13F 2018-09-30 2018-11-14
D. E. SHAW & COMPANY ., INC. 793,082 0.00 2867 155,699 1.5071% 13F 2018-09-30 2018-11-14
How long will the market ignore that?
Hov:
Markets can stay irrational longer than the retail longs can stay sane. I've seen this phenomena few times, and it happens quite often.
I'd say the sign of capitulation would be when B.Liu throws in a white towel, or covers her short position -- whichever she's been doing (I'm almost sure it's the latter, though). Then, we'll see a massive turnaround. When that happens is anyone's guess...
Morgan Stanley sold 192K share, kept 36K shares
Paloma Partners sold out, 183K shares
Goldman Sachs sold 334K shares, kept 123K shares
Vanguard group sold out completely, all 1.773M shares